INKT Key Statistics, Chart & Performance
The current stock price of INKT is 12.332 USD. In the past month the price decreased by -4.54%. In the past year, price increased by 69.63%.
INKT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.74 | 396.49B | ||
| AMGN | AMGEN INC | 15.1 | 177.79B | ||
| GILD | GILEAD SCIENCES INC | 14.84 | 150.78B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 27.32 | 120.32B | ||
| REGN | REGENERON PHARMACEUTICALS | 18.11 | 85.69B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 796.77 | 53.68B | ||
| INSM | INSMED INC | N/A | 37.68B | ||
| NTRA | NATERA INC | N/A | 33.04B | ||
| BIIB | BIOGEN INC | 11.32 | 27.79B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.65 | 21.19B | ||
| INCY | INCYTE CORP | 16.66 | 21.00B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 21.97B |
Related stock screener links
About INKT
Company Profile
MiNK Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of allogeneic invariant natural killer T cell therapies to treat cancer and other immune mediated diseases. The company is headquartered in New York City, New York and currently employs 23 full-time employees. The company went IPO on 2021-10-15. The firm is engaged in the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. Its advanced product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy designed to provide transformative treatment options. AgenT-797 is an iNKT cell therapy that harnesses the dual power of innate and adaptive immunity. In addition, it is advancing a pipeline of allogeneic, engineered iNKT programs. Its two advanced preclinical engineered programs are MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen (BCMA), and MiNK-215, an IL-15 armored tumor stromal targeting FAP-CAR-iNKT program.
Company Info
MINK THERAPEUTICS INC
149 Fifth Avenue, Suite 500
New York City NEW YORK US
Employees: 23
Phone: 12129948250
MINK THERAPEUTICS INC / INKT FAQ
Can you describe the business of MINK THERAPEUTICS INC?
MiNK Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of allogeneic invariant natural killer T cell therapies to treat cancer and other immune mediated diseases. The company is headquartered in New York City, New York and currently employs 23 full-time employees. The company went IPO on 2021-10-15. The firm is engaged in the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. Its advanced product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy designed to provide transformative treatment options. AgenT-797 is an iNKT cell therapy that harnesses the dual power of innate and adaptive immunity. In addition, it is advancing a pipeline of allogeneic, engineered iNKT programs. Its two advanced preclinical engineered programs are MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen (BCMA), and MiNK-215, an IL-15 armored tumor stromal targeting FAP-CAR-iNKT program.
What is the stock price of MINK THERAPEUTICS INC today?
The current stock price of INKT is 12.332 USD. The price decreased by -0.55% in the last trading session.
What is the dividend status of MINK THERAPEUTICS INC?
INKT does not pay a dividend.
What is the ChartMill rating of MINK THERAPEUTICS INC stock?
INKT has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
When does MINK THERAPEUTICS INC (INKT) report earnings?
MINK THERAPEUTICS INC (INKT) will report earnings on 2026-03-16, after the market close.
Can you provide the ownership details for INKT stock?
You can find the ownership structure of MINK THERAPEUTICS INC (INKT) on the Ownership tab.
INKT Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to INKT. When comparing the yearly performance of all stocks, INKT is one of the better performing stocks in the market, outperforming 86.37% of all stocks.
INKT Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
INKT Forecast & Estimates
8 analysts have analysed INKT and the average price target is 39.78 USD. This implies a price increase of 222.58% is expected in the next year compared to the current price of 12.332.